Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-UK's mutating variant a concern as it might undermine vaccines, scientist says

Thu, 11th Feb 2021 08:41

* British variant mutation is a worry - UK genetic chief

* Some mutations may undermine vaccines - genetic chief

* Vaccines so far effective, drug companies say

* UK variant will sweep the world - UK genetic chief

* Says: We'll be doing this a decade from now
(Recasts headline and lead, adds Johnson)

By Guy Faulconbridge

LONDON, Feb 11 (Reuters) - The coronavirus variant first
found in the British region of Kent is a concern because it is
mutating and so could undermine the protection given by vaccines
against developing COVID-19, the head of the UK's genetic
surveillance programme said.

She also said the British variant was dominant in the
country and was likely "to sweep the world, in all probability".

The coronavirus has killed 2.35 million people and turned
normal life upside down for billions, but a few new worrying
variants out of thousands have raised fears that vaccines will
need to be tweaked and people may require booster shots.

Sharon Peacock, director of the COVID-19 Genomics UK
consortium, said vaccines were so far effective against the
variants in the United Kingdom, but that mutations could
potentially undermine the shots.

"What's concerning about this is that the 1.1.7 variant that
we have had circulating for some weeks and months is beginning
to mutate again and get new mutations which could affect the way
that we handle the virus in terms of immunity and effectiveness
of vaccines," Peacock told the BBC.

"It's concerning that the 1.1.7, which is more
transmissible, which has swept the country, is now mutating to
have this new mutation that could threaten vaccination."

That new mutation, first identified in Bristol in southwest
England, has been designated a "Variant of Concern", by the New
and Emerging Respiratory Virus Threats Advisory Group.

Britain's chief scientific adviser, Patrick Vallance, said
the Bristol variant had one of the same mutations as the South
African. "It is not surprising that it has happened and it will
happen elsewhere as well," he said on Wednesday.

"In getting that variant it does make it slightly more
likely to look different to the immune system so we need to
watch out for it, we need to measure it, we need to keep on top
of it and need to keep testing the vaccine effects in this
situation."

There are so far 21 cases of that variant which has E484K
mutation, which occurs on the spike protein of the virus, the
same change as has been seen in the South African and Brazilian
variants.

"One has to be a realist that this particular mutation has
arisen in our kind of communal garden lineage now, at least five
times - five separate times. And so this is going to keep
popping up," Peacock said.

British people should expect to receive repeated
vaccinations against COVID-19 in future to keep pace with
mutations of the virus, Prime Minister Boris Johnson said on
Wednesday.

There are three major known variants that are worrying
scientists: the South African variant, known by scientists as
20I/501Y.V2 or B.1.351; the British variant known as 20I/501Y.V1
or B.1.1.7; and the Brazilian variant known as P.1.

The British variant, which is more infectious but not
necessarily more deadly than others, was likely "to sweep the
world", Peacock said.

"Once we get on top of (the virus) or it mutates itself out
of being virulent - causing disease - then we can stop worrying
about it. But I think, looking in the future, we're going to be
doing this for years. We're still going to be doing this 10
years down the line, in my view."

The two COVID-19 vaccines developed by Pfizer/BioNTech and
AstraZeneca protect against the main British variant.
(Reporting by Guy Faulconbridge; Editing by Kate Holton and
Nick Macfie)

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.